Altimmune Financials
This page shows Altimmune (ALT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Altimmune has an operating margin of -515860.0%, meaning the company retains $-515860 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -22518.5% the prior year.
Altimmune's revenue declined 95.3% year-over-year, from $426K to $20K. This contraction results in a growth score of 0/100.
Altimmune carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 13.11, Altimmune holds $13.11 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Altimmune passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Altimmune generates $0.84 in operating cash flow (-$79.8M OCF vs -$95.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Altimmune earns $-11463.6 in operating income for every $1 of interest expense (-$103.2M vs $9K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Altimmune generated $20K in revenue in fiscal year 2024. This represents a decrease of 95.3% from the prior year.
Altimmune's EBITDA was -$102.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.8% from the prior year.
Altimmune reported -$95.1M in net income in fiscal year 2024. This represents a decrease of 7.5% from the prior year.
Altimmune earned $-1.34 per diluted share (EPS) in fiscal year 2024. This represents an increase of 19.3% from the prior year.
Altimmune held $36.9M in cash against $0 in long-term debt as of fiscal year 2024.
Altimmune had 72M shares outstanding in fiscal year 2024. This represents an increase of 2.4% from the prior year.
Altimmune's operating margin was -515860.0% in fiscal year 2024, reflecting core business profitability. This is down 493341.5 percentage points from the prior year.
Altimmune's net profit margin was -475295.0% in fiscal year 2024, showing the share of revenue converted to profit. This is down 454532.8 percentage points from the prior year.
Altimmune invested $82.2M in research and development in fiscal year 2024. This represents an increase of 25.0% from the prior year.
ALT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K0.0% | $5K0.0% | $5K-86.5% | $37K-89.8% | $362K+5933.3% | $6K-71.4% | $21K | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $15.0M-13.2% | $17.2M+8.9% | $15.8M-6.4% | $16.9M-8.0% | $18.4M+38.7% | $13.3M-23.2% | $17.2M-10.1% | $19.2M |
| SG&A Expenses | $5.9M+3.7% | $5.7M-5.0% | $6.0M+38.3% | $4.3M-4.0% | $4.5M-5.2% | $4.8M+5.1% | $4.5M+19.1% | $3.8M |
| Operating Income | -$20.9M+9.0% | -$22.9M-5.1% | -$21.8M+35.1% | -$33.6M-49.2% | -$22.5M-25.2% | -$18.0M+17.2% | -$21.8M+5.8% | -$23.1M |
| Interest Expense | $495K+87.5% | $264K+26300.0% | $1K-50.0% | $2K-93.1% | $29K+1350.0% | $2K0.0% | $2K+101.1% | -$183K |
| Income Tax | $0 | $0+100.0% | -$681K | N/A | $0 | $0 | $0 | $0 |
| Net Income | -$19.0M+14.1% | -$22.1M-13.1% | -$19.6M+38.1% | -$31.6M-53.1% | -$20.7M-28.7% | -$16.1M+20.0% | -$20.1M+7.3% | -$21.7M |
| EPS (Diluted) | $-0.21+22.2% | $-0.27-3.8% | $-0.26+52.7% | $-0.55-41.0% | $-0.39-21.9% | $-0.32+20.0% | $-0.40+14.9% | $-0.47 |
ALT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $218.4M+14.8% | $190.3M+21.0% | $157.3M-25.3% | $210.6M+26.5% | $166.6M-9.1% | $183.3M-2.0% | $187.1M-9.6% | $206.9M |
| Current Assets | $216.6M+15.0% | $188.4M+21.4% | $155.3M-25.9% | $209.6M+37.0% | $153.0M-9.8% | $169.5M-2.1% | $173.1M-10.2% | $192.8M |
| Cash & Equivalents | $61.2M-66.6% | $183.1M+272.9% | $49.1M-63.7% | $135.1M+55.6% | $86.9M-15.1% | $102.4M-2.2% | $104.7M-5.8% | $111.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $32.8M+13.3% | $29.0M+91.9% | $15.1M-8.7% | $16.5M+2.3% | $16.2M+3.7% | $15.6M-19.4% | $19.4M-10.6% | $21.6M |
| Current Liabilities | $12.6M+36.7% | $9.2M-5.9% | $9.8M-19.3% | $12.1M+2.3% | $11.9M+3.8% | $11.4M-23.5% | $15.0M-12.3% | $17.1M |
| Long-Term Debt | $14.4M+0.8% | $14.3M | N/A | N/A | $4.3M+3.4% | $4.2M-5.3% | $4.4M-4.0% | $4.6M |
| Total Equity | $185.6M+15.0% | $161.4M+13.5% | $142.2M-26.8% | $194.1M+29.1% | $150.4M-10.3% | $167.7M0.0% | $167.7M-9.5% | $185.3M |
| Retained Earnings | -$622.1M-3.2% | -$603.1M-3.8% | -$581.0M-24.6% | -$466.3M-7.3% | -$434.7M-5.0% | -$414.0M-4.0% | -$398.0M-5.3% | -$377.9M |
ALT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.9M+38.5% | -$19.4M-14.9% | -$16.8M-1.9% | -$16.5M+19.3% | -$20.5M-5.7% | -$19.4M+0.1% | -$19.4M-12.1% | -$17.3M |
| Capital Expenditures | $0 | N/A | N/A | $0 | $0+100.0% | -$4K-107.8% | $51K+34.2% | $38K |
| Free Cash Flow | -$11.9M | N/A | N/A | -$16.5M+19.3% | -$20.5M-5.7% | -$19.4M+0.4% | -$19.5M-12.2% | -$17.3M |
| Investing Cash Flow | -$149.3M-247.7% | $101.1M+2082.1% | -$5.1M+35.9% | -$8.0M-280.8% | $4.4M+10.4% | $4.0M-70.0% | $13.3M+1256.0% | $981K |
| Financing Cash Flow | $39.3M-24.7% | $52.2M+53.1% | $34.1M-53.1% | $72.8M+12273.1% | $588K-95.5% | $13.1M+4426.2% | -$302K-602.3% | -$43K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ALT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -417180.0%+41260.0pp | -458440.0%-22140.0pp | -436300.0%-345427.0pp | -90873.0%-84646.4pp | -6226.5%+293890.2pp | -300116.7%-196502.4pp | -103614.3% | N/A |
| Net Margin | -380280.0%+62640.0pp | -442920.0%-51420.0pp | -391500.0%-305983.8pp | -85516.2%-79806.0pp | -5710.2%+261973.1pp | -267683.3%-172092.8pp | -95590.5% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.7%+2.9pp | -11.6%+0.8pp | -12.4%+2.6pp | -15.0%-2.6pp | -12.4%-3.7pp | -8.8%+2.0pp | -10.7%-0.3pp | -10.5% |
| Current Ratio | 17.18-3.3 | 20.44+4.6 | 15.85-1.4 | 17.26+4.4 | 12.89-1.9 | 14.82+3.2 | 11.58+0.3 | 11.31 |
| Debt-to-Equity | 0.08-0.0 | 0.09-0.0 | 0.11+0.0 | 0.09+0.1 | 0.030.0 | 0.020.0 | 0.030.0 | 0.02 |
| FCF Margin | -237940.0% | N/A | N/A | -44683.8%-39024.4pp | -5659.4%+317457.3pp | -323116.7%-230459.5pp | -92657.1% | N/A |
Similar Companies
Frequently Asked Questions
What is Altimmune's annual revenue?
Altimmune (ALT) reported $20K in total revenue for fiscal year 2024. This represents a -95.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Altimmune's revenue growing?
Altimmune (ALT) revenue declined by 95.3% year-over-year, from $426K to $20K in fiscal year 2024.
Is Altimmune profitable?
No, Altimmune (ALT) reported a net income of -$95.1M in fiscal year 2024, with a net profit margin of -475295.0%.
What is Altimmune's earnings per share (EPS)?
Altimmune (ALT) reported diluted earnings per share of $-1.34 for fiscal year 2024. This represents a 19.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Altimmune's EBITDA?
Altimmune (ALT) had EBITDA of -$102.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Altimmune's operating margin?
Altimmune (ALT) had an operating margin of -515860.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Altimmune's net profit margin?
Altimmune (ALT) had a net profit margin of -475295.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Altimmune's operating cash flow?
Altimmune (ALT) generated -$79.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Altimmune's total assets?
Altimmune (ALT) had $139.3M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Altimmune spend on research and development?
Altimmune (ALT) invested $82.2M in research and development during fiscal year 2024.
How many shares does Altimmune have outstanding?
Altimmune (ALT) had 72M shares outstanding as of fiscal year 2024.
What is Altimmune's current ratio?
Altimmune (ALT) had a current ratio of 13.11 as of fiscal year 2024, which is generally considered healthy.
What is Altimmune's debt-to-equity ratio?
Altimmune (ALT) had a debt-to-equity ratio of 0.13 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Altimmune's return on assets (ROA)?
Altimmune (ALT) had a return on assets of -68.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Altimmune's cash runway?
Based on fiscal year 2024 data, Altimmune (ALT) had $36.9M in cash against an annual operating cash burn of $79.8M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Altimmune's Piotroski F-Score?
Altimmune (ALT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Altimmune's earnings high quality?
Altimmune (ALT) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Altimmune cover its interest payments?
Altimmune (ALT) has an interest coverage ratio of -11463.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Altimmune?
Altimmune (ALT) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.